Making meaningful inroads into the rapidly advancing mortality rate from opioid overdose requires a massive increase in the number of naloxone doses available to people at risk, wherever they are and from whoever is close by.  

We need an easier-to-use and lower cost alternative to naloxone nasal sprays.

At Buckle Therapeutics, we are preparing our first product – naloxone in our patented cheek swab applicator – for a clinical trial to demonstrate equivalence to the gold standard of care and for submission to the FDA for approval.

We are committed to doing everything we can to make sure no one dies from an overdose because help did not arrive in time.